Published in the Journal of Clinical Oncology, January 2025
The CheckMate 274 phase III trial provides expanded efficacy data on adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma (MIUC) following radical resection. With a median follow-up of 36.1 months, the study confirms a consistent benefit in disease-free survival (DFS) and overall survival (OS). The hazard ratio for DFS was 0.71 in the intent-to-treat population and 0.52 in patients with PD-L1 expression ≥1%, while OS showed a hazard ratio of 0.76 and 0.56 in these respective groups. The study also demonstrated continued improvements in non-urothelial tract recurrence-free survival and distant metastasis-free survival.
An exploratory analysis in patients with muscle-invasive bladder cancer (MIBC) further supports the effectiveness of nivolumab regardless of PD-L1 status. Importantly, no new safety concerns emerged, reinforcing adjuvant nivolumab as a standard of care for high-risk MIUC.
A special thanks to all the researchers involved in this important study.
For more details:https://lnkd.in/ecNq9XAn
